PTC Therapeutics Inc PTCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTCT is a good fit for your portfolio.
News
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
-
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
-
PTC Therapeutics Provides Key Regulatory Updates
-
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $25.97
- Day Range
- $25.17–26.27
- 52-Week Range
- $17.53–59.84
- Bid/Ask
- $18.60 / $35.00
- Market Cap
- $1.95 Bil
- Volume/Avg
- 754,373 / 870,289
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 995
- Website
- https://www.ptcbio.com
Comparables
Valuation
|
Metric
|
PTCT
|
BLUE
|
FDMT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.47 | 3.47 |
Price/Sales | 2.03 | 4.53 | 46.85 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PTCT
|
BLUE
|
FDMT
|
|---|---|---|---|
Quick Ratio | 1.72 | 1.24 | 15.21 |
Current Ratio | 2.02 | 1.55 | 15.65 |
Interest Coverage | −4.39 | — | — |
Quick Ratio
PTCT
BLUE
FDMT
Profitability
|
Metric
|
PTCT
|
BLUE
|
FDMT
|
|---|---|---|---|
Return on Assets (Normalized) | −20.32% | −12.29% | −25.94% |
Return on Equity (Normalized) | — | −30.63% | −28.64% |
Return on Invested Capital (Normalized) | −34.36% | −15.27% | −31.25% |
Return on Assets
PTCT
BLUE
FDMT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ptslqwxt | Zyr | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vrzjbfcp | Bqgzgv | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wppnjfy | Rbjnjg | $99.6 Bil | |
MRNA
| Moderna Inc | Lpnwlyf | Srp | $38.8 Bil | |
ARGX
| argenx SE ADR | Wkqqvcbn | Kprdv | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Yfndlfyq | Shcw | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kvdbcyb | Mmfrqd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ddyjcbszm | Crgkkp | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fwyqslsmt | Sdtldz | $12.4 Bil | |
INCY
| Incyte Corp | Kpfkdhtyw | Nkqkhs | $11.9 Bil |